Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4865269 | 0.99 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1RXFP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6392840 | 0.91 | RAB9A (0.43) | RAB9ASMN1; SMN2NPC1RXFP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6392833 | 0.87 | RAB9A (0.44) | RAB9ASMN1; SMN2NPC1RXFP1L3MBTL1 | |
| Carbamic Acid SCHEMBL4876208 | 0.86 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1RXFP1L3MBTL1 | |
| SCHEMBL4876201 | 0.85 | RAB9A (0.43) | RAB9ASMN1; SMN2NPC1RXFP1L3MBTL1 | |
| SCHEMBL14019592 | 0.85 | GAA (0.46) | SMN1; SMN2L3MBTL1ALDH1A1KMT2ANAMPT | |
| Hydrochloric Acid SCHEMBL4875872 | 0.84 | GAA (0.46) | SMN1; SMN2L3MBTL1ALDH1A1KMT2ANAMPT | |
| SCHEMBL14019595 | 0.83 | POLB (0.39) | ALDH1A1 | |
| SCHEMBL14019574 | 0.83 | AOC3 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4873425 | 0.83 | POLB (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20070208068-A1 | Aqueous Composition Comprising Thiazole Derivative | R-TECH UENO, LTD. & ASTELLAS PHARMA INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208068-A1 | Aqueous Composition Comprising Thiazole Derivative | R-TECH UENO, LTD. & ASTELLAS PHARMA INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | RAB9A 2149/4885SMN1; SMN2 3771/4885NPC1 549/4885 |
| US-20070208068-A1 | Aqueous Composition Comprising Thiazole Derivative | SLC5A1, SLC5A2, SLC10A1 | RAB9A 3125/4885SMN1; SMN2 1861/4885NPC1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.